These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20482493)

  • 1. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.
    Chary A; Holodniy M
    Rev Recent Clin Trials; 2010 Sep; 5(3):158-73. PubMed ID: 20482493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
    Chevaliez S
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir for the treatment of chronic hepatitis C.
    You DM; Pockros PJ
    Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
    Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
    Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C therapy in non-genotype 1 patients: the near future.
    Wartelle-Bladou C; Le Folgoc G; Bourlière M; Lecomte L
    J Viral Hepat; 2012 Aug; 19(8):525-36. PubMed ID: 22762136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of current anti-HCV treatment regimens and possible future strategies.
    Neukam K; Macías J; Mira JA; Pineda JA
    Expert Opin Pharmacother; 2009 Feb; 10(3):417-33. PubMed ID: 19191679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
    Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
    Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
    Chevaliez S; Asselah T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S31-41. PubMed ID: 21742299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
    de Bruijne J; Thomas XV; Rebers SP; Weegink CJ; Treitel MA; Hughes E; Bergmann JF; de Knegt RJ; Janssen HL; Reesink HW; Molenkamp R; Schinkel J
    J Viral Hepat; 2013 Nov; 20(11):779-89. PubMed ID: 24168257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.